Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rezvilutamide with ADT and Salvage Radiotherapy for Biochemical Recurrence of Prostate Cancer
NCT06305832Phase 2Recruiting
- Sponsor
- Nanjing Drum-Tower Hospital
- Start
- Sep 2023
- Primary completion
- Mar 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of rezvilutamide in prostate cancer (PCa), sponsored by Nanjing Drum-Tower Hospital. Started Sep 2023; status: recruiting.
02
Drugs
rezvilutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT06305832.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06305832.